PMID- 33813379
OWN - NLM
STAT- MEDLINE
DCOM- 20210413
LR  - 20210413
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 41
IP  - 4
DP  - 2021 Apr
TI  - Therapy-related Myeloid Leukemia With the Translocation t(8;19)(p11;q13) Leading 
      to a KAT6A-LEUTX Fusion Gene.
PG  - 1753-1760
LID - 10.21873/anticanres.14940 [doi]
AB  - BACKGROUND/AIM: The chromosome translocation t(8;19)(p11;q13) has been reported 
      in only six acute myeloid leukemia (AML) patients. We here present the genetic 
      and clinical features of the seventh AML case with this aberration. MATERIALS AND 
      METHODS: Cytogenetic and molecular genetic investigations were performed on 
      leukemic bone marrow cells from a patient with therapy-related AML. RESULTS: A 
      t(8;19)(p11;q13) was found leading to an in-frame fusion of exon 16 of the lysine 
      acetyltransferase 6A gene (KAT6A) from 8p11 with exon 2 of the leucine twenty 
      homeobox gene (LEUTX) from 19q13 resulting in expression of the otherwise silent 
      LEUTX gene in the leukemic cells. The KAT6A-LEUTX protein is predicted to act as 
      a histone acetyltransferase at its amino-terminal-KAT6A moiety but as a homeobox 
      transcription factor at the LEUTX-carboxyl-terminal moiety. CONCLUSION: The 
      present case is the second therapy-related AML, and the third AML overall, in 
      which both a t(8;19)(p11;q13) and its molecular result, a KAT6A-LEUTX fusion 
      gene, are described. The t(8;19)(p11;q13)/KAT6A-LEUTX deregulates transcription 
      and induces leukemogenesis.
FAU - Panagopoulos, Ioannis
AU  - Panagopoulos I
AD  - Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, 
      The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; 
      ioannis.panagopoulos@rr-research.no.
FAU - Andersen, Kristin
AU  - Andersen K
AD  - Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, 
      The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
FAU - Ramslien, Lloyd Frode
AU  - Ramslien LF
AD  - Department of Cancer and Hematological Diseases, Telemark Hospital, Skien, 
      Norway.
FAU - Ikonomou, Ida Munster
AU  - Ikonomou IM
AD  - Department of Pathology, Oslo University Hospital, Oslo, Norway.
FAU - Micci, Francesca
AU  - Micci F
AD  - Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, 
      The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
FAU - Heim, Sverre
AU  - Heim S
AD  - Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, 
      The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
AD  - Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, 
      Norway.
LA  - eng
PT  - Case Reports
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (LEUTX protein, human)
RN  - EC 2.3.1.48 (Histone Acetyltransferases)
RN  - EC 2.3.1.48 (KAT6A protein, human)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/*genetics
MH  - Chemoradiotherapy/*adverse effects
MH  - *Chromosomes, Human, Pair 19
MH  - *Chromosomes, Human, Pair 8
MH  - Female
MH  - Gene Expression Regulation, Leukemic
MH  - *Gene Fusion
MH  - Histone Acetyltransferases/*genetics
MH  - Homeodomain Proteins/*genetics
MH  - Humans
MH  - Leukemia, Myeloid, Acute/diagnosis/drug therapy/*etiology/genetics
MH  - *Translocation, Genetic
MH  - Treatment Outcome
MH  - Uterine Cervical Neoplasms/therapy
OTO - NOTNLM
OT  - Acute myeloid leukemia
OT  - KAT6A
OT  - KAT6A-LEUTX
OT  - LEUTX
OT  - chromosome translocation
OT  - fusion gene
OT  - histone acetyltransferase
OT  - homeobox gene
OT  - t(8;19)(p11;q13)
EDAT- 2021/04/05 06:00
MHDA- 2021/04/14 06:00
CRDT- 2021/04/04 20:59
PHST- 2021/02/03 00:00 [received]
PHST- 2021/02/22 00:00 [revised]
PHST- 2021/02/23 00:00 [accepted]
PHST- 2021/04/04 20:59 [entrez]
PHST- 2021/04/05 06:00 [pubmed]
PHST- 2021/04/14 06:00 [medline]
AID - 41/4/1753 [pii]
AID - 10.21873/anticanres.14940 [doi]
PST - ppublish
SO  - Anticancer Res. 2021 Apr;41(4):1753-1760. doi: 10.21873/anticanres.14940.